BioSpace News Archive

Realm Therapeutics plc announces that its 2018 Annual Report is now available on the Company’s website, www.realmtx.com, and will be posted to those shareholders who have not elected to receive the document electronically.

Facility Footprint Increased to 1.6 Million Square Feet, Target Capacity 230,000+ kg per Annum

Collaboration with Human Epilepsy Project will Enhance Evogen’s Blood-Based Biomarker Test with the Potential to Transform Epilepsy Diagnosis

Highest Dose CBD Capsule on the Canadian Market Fills Unmet Need

Acceptance for late breaking oral presentation underscores the oncology community’s interest in Namodenoson as a potential treatment for liver cancer

Nordic Nanovector ASA announces that the Safety Review Committee for the ongoing LYMRIT 37-05 clinical trial of single-administration Betalutin® in patients with relapsed/refractory diffuse large B-cell lymphoma not eligible for stem cell transplantation has now reviewed safety data from the first three cohorts of patients.

Immunovia announced that Prof. Stephen Pereira and his team at the institute for Liver and Digestive Health, University College London (UCL) will expand the prospective collection of blood samples funded by Immunovia and that started with the PanSYM-1 pilot study.

Tumor-localizing properties of bispecific antibody demonstrated by live imaging

American Society of Plastic Surgeons reveals the most and least expensive surgical procedures and national average of cosmetic surgical fees in 2018

Magellan Health, Inc. announced that it will report its earnings for the first quarter ended on March 31, 2019 at approximately 6:30 a.m. Eastern Time on Thursday, May 2, 2019.